SCHOLAR ROCK HOLDING CORPORATION Operating Expenses
SCHOLAR ROCK HOLDING CORPORATION (SRRK) reported Operating Expenses of $108.90 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-06
- SCHOLAR ROCK HOLDING CORPORATION operating expenses for the quarter ending 2026-06-30 was $108.90M, a 2.86% decline year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION operating expenses for the quarter ending 2026-03-31 was $102.02M, a 32.33% increase year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION operating expenses for the quarter ending 2025-12-31 was $91.90M, a 32.50% increase year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION operating expenses for the quarter ending 2025-09-30 was $103.55M, a 59.85% increase year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION operating expenses for fiscal 2025 was $384.64M, a 52.60% increase from fiscal 2024.
- SCHOLAR ROCK HOLDING CORPORATION operating expenses for fiscal 2024 was $252.05M, a 47.15% increase from fiscal 2023.
- SCHOLAR ROCK HOLDING CORPORATION operating expenses for fiscal 2023 was $171.29M, a 2.23% increase from fiscal 2022.
- SCHOLAR ROCK HOLDING CORPORATION operating expenses for fiscal 2022 was $167.56M, a 12.66% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $108.90M 10-Q · filed 2026-08-06 | $210.92M 10-Q · filed 2026-08-06 | $302.81M derived: sum of 3 quarters · filed 2026-08-06 | $406.36M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $102.02M 10-Q · filed 2026-05-07 | $193.91M derived: sum of 2 quarters · filed 2026-05-07 | $297.46M derived: sum of 3 quarters · filed 2026-05-07 | $409.57M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $91.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $195.45M derived: sum of 2 quarters · filed 2026-03-03 | $307.56M derived: sum of 3 quarters · filed 2026-08-06 | $384.64M 10-K · filed 2026-03-03 |
| 2025-09-30 | $103.55M 10-Q · filed 2025-11-14 | $215.66M derived: sum of 2 quarters · filed 2026-08-06 | $292.75M 10-Q · filed 2025-11-14 | $362.11M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $112.11M 10-Q · filed 2026-08-06 | $189.20M 10-Q · filed 2026-08-06 | $258.56M derived: sum of 3 quarters · filed 2026-08-06 | $323.34M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $77.09M 10-Q · filed 2026-05-07 | $146.45M derived: sum of 2 quarters · filed 2026-05-07 | $211.23M derived: sum of 3 quarters · filed 2026-05-07 | $270.73M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $69.36M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $134.14M derived: sum of 2 quarters · filed 2026-03-03 | $193.63M derived: sum of 3 quarters · filed 2026-03-03 | $252.05M 10-K · filed 2026-03-03 |
| 2024-09-30 | $64.78M 10-Q · filed 2025-11-14 | $124.28M derived: sum of 2 quarters · filed 2025-11-14 | $182.70M 10-Q · filed 2025-11-14 | $230.73M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $59.50M 10-Q · filed 2025-08-06 | $117.92M 10-Q · filed 2025-08-06 | $165.95M derived: sum of 3 quarters · filed 2025-08-06 | $209.62M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $58.42M 10-Q · filed 2025-05-14 | $106.45M derived: sum of 2 quarters · filed 2025-05-14 | $150.12M derived: sum of 3 quarters · filed 2025-05-14 | $189.21M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $48.03M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $91.70M derived: sum of 2 quarters · filed 2025-02-27 | $130.79M derived: sum of 3 quarters · filed 2025-02-27 | $171.29M 10-K · filed 2025-02-27 |
| 2023-09-30 | $43.67M 10-Q · filed 2024-11-12 | $82.75M derived: sum of 2 quarters · filed 2024-11-12 | $123.26M 10-Q · filed 2024-11-12 | $163.69M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $39.08M 10-Q · filed 2024-08-08 | $79.59M 10-Q · filed 2024-08-08 | $120.02M derived: sum of 3 quarters · filed 2024-08-08 | $163.88M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $40.51M 10-Q · filed 2024-05-07 | $80.94M derived: sum of 2 quarters · filed 2024-05-07 | $124.80M derived: sum of 3 quarters · filed 2024-05-07 | $167.95M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $40.43M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $84.29M derived: sum of 2 quarters · filed 2024-03-19 | $127.44M derived: sum of 3 quarters · filed 2024-03-19 | $167.56M 10-K · filed 2024-03-19 |
| 2022-09-30 | $43.86M 10-Q · filed 2023-11-07 | $87.01M derived: sum of 2 quarters · filed 2023-11-07 | $127.14M 10-Q · filed 2023-11-07 | $166.55M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $43.15M 10-Q · filed 2023-08-09 | $83.27M 10-Q · filed 2023-08-09 | $122.69M derived: sum of 3 quarters · filed 2023-08-09 | $165.23M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $40.13M 10-Q · filed 2023-05-09 | $79.54M derived: sum of 2 quarters · filed 2023-05-09 | $122.08M derived: sum of 3 quarters · filed 2023-05-09 | $156.95M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $39.41M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $81.95M derived: sum of 2 quarters · filed 2023-03-07 | $116.82M derived: sum of 3 quarters · filed 2023-03-07 | $148.74M 10-K · filed 2023-03-07 |
| 2021-09-30 | $42.54M 10-Q · filed 2022-11-14 | $77.41M derived: sum of 2 quarters · filed 2022-11-14 | $109.32M 10-Q · filed 2022-11-14 | $138.86M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $34.87M 10-Q · filed 2022-08-08 | $66.78M 10-Q · filed 2022-08-08 | $96.32M derived: sum of 3 quarters · filed 2022-08-08 | $122.98M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $31.91M 10-Q · filed 2022-05-16 | $61.45M derived: sum of 2 quarters · filed 2022-05-16 | $88.11M derived: sum of 3 quarters · filed 2022-05-16 | $111.47M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $29.54M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-07 | $56.20M derived: sum of 2 quarters · filed 2022-03-07 | $79.56M derived: sum of 3 quarters · filed 2022-03-07 | $102.28M 10-K · filed 2022-03-07 |
| 2020-09-30 | $26.66M 10-Q · filed 2021-11-09 | $50.02M derived: sum of 2 quarters · filed 2021-11-09 | $72.74M 10-Q · filed 2021-11-09 | $92.66M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | $23.36M 10-Q · filed 2021-08-10 | $46.09M 10-Q · filed 2021-08-10 | $66.01M derived: sum of 3 quarters · filed 2021-08-10 | $87.89M derived: sum of 4 quarters · filed 2021-08-10 |
| 2020-03-31 | $22.72M 10-Q · filed 2021-05-13 | $42.64M derived: sum of 2 quarters · filed 2021-05-13 | $64.52M derived: sum of 3 quarters · filed 2021-05-13 | $82.95M derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | $19.92M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | $41.80M derived: sum of 2 quarters · filed 2021-03-09 | $60.23M derived: sum of 3 quarters · filed 2021-03-09 | $75.03M 10-K · filed 2021-03-09 |
| 2019-09-30 | $21.88M 10-Q · filed 2020-11-09 | $40.30M derived: sum of 2 quarters · filed 2020-11-09 | $55.11M 10-Q · filed 2020-11-09 | $70.67M derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-06-30 | $18.43M 10-Q · filed 2020-08-07 | $33.23M 10-Q · filed 2020-08-07 | $48.79M derived: sum of 3 quarters · filed 2020-08-07 | $60.03M derived: sum of 4 quarters · filed 2020-08-07 |
| 2019-03-31 | $14.81M 10-Q · filed 2020-05-07 | $30.37M derived: sum of 2 quarters · filed 2020-05-07 | $41.60M derived: sum of 3 quarters · filed 2020-05-07 | $56.49M derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | $15.56M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $26.79M derived: sum of 2 quarters · filed 2020-03-12 | $41.68M derived: sum of 3 quarters · filed 2020-03-12 | $50.69M 10-K · filed 2020-03-12 |
| 2018-09-30 | $11.23M 10-Q · filed 2019-11-12 | $26.12M derived: sum of 2 quarters · filed 2019-11-12 | $35.13M 10-Q · filed 2019-11-12 | $43.59M derived: sum of 4 quarters · filed 2019-11-12 |
| 2018-06-30 | $14.88M 10-Q · filed 2019-08-14 | $23.90M 10-Q · filed 2019-08-14 | $32.36M derived: sum of 3 quarters · filed 2019-08-14 | $38.30M derived: sum of 4 quarters · filed 2019-08-14 |
| 2018-03-31 | $9.02M 10-Q · filed 2019-05-15 | $17.47M derived: sum of 2 quarters · filed 2019-05-15 | $23.42M derived: sum of 3 quarters · filed 2019-05-15 | $29.30M derived: sum of 4 quarters · filed 2019-05-15 |
| 2017-12-31 | $8.46M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-19 | $14.40M derived: sum of 2 quarters · filed 2019-03-19 | $20.29M derived: sum of 3 quarters · filed 2019-03-19 | $25.03M 10-K · filed 2019-03-19 |
| 2017-09-30 | $5.94M 10-Q · filed 2018-11-08 | $11.83M derived: sum of 2 quarters · filed 2018-11-08 | $16.57M 10-Q · filed 2018-11-08 | |
| 2017-06-30 | $5.89M 10-Q · filed 2018-08-08 | $10.63M 10-Q · filed 2018-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |